People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Chinook Therapeutics U.S., Inc. | — | Biotechnology | Series D+ | $180.0M | $4.5B | 2020 |
| Rasberry Futures LLC | — | Other | Series A | $4.7M | $70.4M | 2017 |
| Alcyone Resources Ltd | — | Other | Seed | $1.4M | $25.6M | 2012 |
Andrew King at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew King on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Srinivas Akkaraju | 1 | 10 |
| Jeremy Caldwell | 1 | 4 |
| Andrew Richards | 1 | 3 |
| Sam Hall | 1 | 3 |
| Trevor Harris | 1 | 2 |
| Preston Klassen | 1 | 2 |
| Srini Akkaraju | 1 | 2 |
| Paul Eisenberg | 1 | 2 |
| Tom Frolich | 1 | 1 |
| Eric Dobmeier | 1 | 1 |
| Alan Glicklich | 1 | 1 |
| Charles Morgan | 1 | 1 |
| Ian McCubbing | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.